% | $
Quotes you view appear here for quick access.

Sangamo Biosciences Inc. Message Board

  • gswkool gswkool Jul 16, 2012 4:33 PM Flag


    Shares of Alnylam ALNY +53.04% today after it released positive results from a Phase I clinical study for its drug candidate ALN-TTR02. The company is testing the compound on patients with a genetic disease known as TTR-mediated amyloidosis, or ATTR. ALN-TTRO2 is part of a new class of gene-targeting drugs known as RNAi therapeutics.

    Alnylam rocked it on Phase I and the shares responded. They rocked it for a drug that treats I believe 200K patients and they have orphan drug designation.

    Can't imagine what will happen if positive news for HIV treatment comes out of SGMO. Even phase I news that shows a response.....

    Should get interesting over the next several months...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
5.51-0.41(-6.93%)Jun 24 4:00 PMEDT